Epizyme Inc (EPZM)

NASDAQ
5.330
-0.140(-2.56%)
After Hours
5.300
-0.030(-0.561%)
- Real-time Data
  • Volume:
    477,211
  • Bid/Ask:
    5.300/5.410
  • Day's Range:
    5.300 - 5.500

EPZM Overview

Prev. Close
5.47
Day's Range
5.3-5.5
Revenue
32.59M
Open
5.46
52 wk Range
4.72-14.3
EPS
-2.53
Volume
477,211
Market Cap
544.99M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,135,700
P/E Ratio
-
Beta
1.2
1-Year Change
-54.56%
Shares Outstanding
102,249,517
Next Earnings Date
Nov 03, 2021
What is your sentiment on Epizyme Inc?
or
Market is currently closed. Voting is open during market hours.

Epizyme Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Epizyme Inc Company Profile

Epizyme Inc Company Profile

Employees
304

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Read More
  • Medium target $22.50, high estimate $36. I like the odd 👍👍
    0
    • and now is 6, do you want buy more?
      0
  • nice terending
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.